Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics.
The effects of apomorphine, a stimulant of dopamine autoreceptors, were studied in 12 chronic schizophrenics on neuroleptic treatment; both subcutaneous and intravenous administration were used. Apomorphine has been reported to have therapeutic effects in previous studies but, we were not able to confirm any significant and specific differences in psychotic symptoms or tardive dyskinesia scores with apomorphine administration, compared with placebo. These results do not support the importance of dopamine autoreceptors in the regulation of schizophrenic and dyskinetic symptoms in chronic neuroleptic-treated patients.
D000328:Adult; D001058:Apomorphine / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D001058:Apomorphine